Compare CRBP & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBP | ARAY |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 68.6M |
| IPO Year | 2014 | 2006 |
| Metric | CRBP | ARAY |
|---|---|---|
| Price | $8.38 | $0.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $46.17 | $3.50 |
| AVG Volume (30 Days) | 145.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 64.31 | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $220.00 | $4.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $0.50 |
| 52 Week High | $20.56 | $2.10 |
| Indicator | CRBP | ARAY |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 36.27 |
| Support Level | $8.39 | $0.50 |
| Resistance Level | $8.43 | $1.12 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 79.61 | 47.40 |
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.